Apart from the PD-L1 expression level, various factors, including tumor-infiltrating lymphocytes, tumor mutation burden, neoantigens, and unidentified activated oncogenic pathways, impact patient responses to treatment. The gene discussed is CD274; the disease is neoplasm.